Drug Trial Radar · NCT07472790
A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jul 31, 2026
Primary completion
Apr 30, 2028
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A single-arm clinical study on the efficacy and safety of the novel oncolytic virus Ad-TD-nsIL12 combined with PD-1 inhibitors in the treatment of recurrent high-grade glioma
Conditions
- High-grade Glioma
Interventions
Novel oncolytic virus Ad-TD-nsIL12(BioTTT001)Biological
Inject Ad-TD-nsIL12 into the tumor via Ommaya reservoir, administering on days 1, 4, and 7, and infuse a PD-1 inhibitor on day 9.Ad-TD-nsIL12 is injected every 21 days (± 3 days) as appropriate in subsequent cycles. On the 7th day (±3 days) after oncolytic virus administration each cycle, a PD-1 inhibitor is given, or until disease progression or the occurrence of intolerable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of the efficacy of the novel oncolytic virus Ad-TD-nsIL12 combined with PD-1 inhibitors in treating recurrent HGG patientsTime frame: Until death,12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sanbo Brain Hospital, Capital Medical University
Beijing, Chaoyang District, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.